Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy

Anti-Cancer Drug Design

Volumn 14, Issue 2, 1999, Pages 93-106

  Desbene, Stéphanie ^a   Van Dufat Trinh, Hanh ^a   Michel, Sylvie ^a   Tillequin, François ^a   Koch, Michel ^a   Schmidt, Frédéric ^b   Florent, Jean Claude ^b   Monneret, Claude ^b   Straub, Rainer ^c   Czech, Jörg ^c   Gerken, Manfred ^c   Bosslet, Klaus ^c  

^a CNRS   (France)

^b INSTITUT CURIE   (France)

^c SANOFI   (France)

Author keywords

ADEPT; Cancer; Dipyridamole; Doxorubicin; Multidrug resistance; Prodrug; Quinine; Verapamil

Indexed keywords

DIPYRIDAMOLE; GLUCURONIC ACID; PRODRUG; QUININE; VERAPAMIL;

ARTICLE; CANCER CHEMOTHERAPY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; ENZYME ACTIVITY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIPYRIDAMOLE; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG STABILITY; ESCHERICHIA COLI; GLUCURONATES; GLUCURONIC ACID; GLUCURONIDASE; HUMANS; HYDROLYSIS; LEUKEMIA L1210; PRODRUGS; QUININE; SPECTROPHOTOMETRY, ULTRAVIOLET; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; VERAPAMIL;

CINCHONA PUBESCENS;

EID: 0032970951     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Baggetto L. (1997) Non P-glycoprotein novel proteins involved in human cancer multidrug resistance. Bulletin du Cancer, 84, 385.
2. Bagshawe K.D. (1987) Antibody directed enzymes revive anti-cancer prodrugs concept. British Journal of Cancer, 56, 531.
3. Bagshawe K.D. (1995) Antibody-directed enzyme prodrug therapy: a review. Drug Development Research, 34, 220.
4. Belhoussine R., Moriani H., Manfait M. (1997) Effet de la quinine sur la résistance multiple et la distribution intracellulaire de la pirarubicine dans les cellules tumorales LR73: étude comparative avec le vérapamil et le S9788 par microspectrofluorimétrie confocale laser. Bulletin du Cancer, 84, 343.
5. Bennis S., Ichas F., Robert J. (1995) Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line. International Journal of Cancer, 62, 283.
6. Bieder J. (1993) Multidrug resistance. Drug News & Perspectives, 7, 475.
7. Boer R., Gekeler V. (1995) Drugs of the Future, 20, 499.
8. Bollenback G.N., Long J.W., Benjamin D.G., Lindquist J.A. (1955) The synthesis of aryl-D-glucopyranosiduronic acids. Journal of the American Chemical Society, 77, 3310.
9. Borst P., Schinkel A. (1997) Genetic dissection of the function of mammalian P-glycoproteins. Trends in Genetics, 13, 217.
10. Bosch I., Croop J. (1996) P glycoprotein multidrug resistance and cancer. Biochimica et Biophysica Acta, 1288, F37.
11. Bosslet K., Czech J., Lorenz P., Sedlacek H.H., Schuermann M., Seemann G. (1992) Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation. British Journal of Cancer, 65, 234.
12. Bosslet K., Czech J., Hoffmann D. (1994) Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Research, 54, 2151.
13. Chauffert B., Pelletier H., Corda C., Solary E., Bedenne L., Caillot D., Martin F. (1990) Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice. British Journal of Cancer, 62, 395.
14. Cole S., Sparks K., Fraser K., Loe D., Grant C., Wilson G., Deeley R. (1994) Pharmacological characterization of multidrug resistant mrp-transfected human tumor cells. Cancer Research, 54, 5902.
15. Curtin N., Turner D. (1997) Reversal of drug resistance by dipyridamole in multidrug resistance-associated protein (MRP)-overexpressing cells. Proceedings of the American Association for Cancer Research, 38, 3972.
16. Damle B., Sridhar R., Desai P. (1994) Dipyridamole modulates multidrug resistance and intracellular as well as nuclear levels of doxorubicin in B16 melanoma cells. International Journal of Cancer, 56, 113.
17. Desai P.B., Duan J., Sridhar R., Damle B.D. (1997) Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole. Methods and Findings in Experimental and Clinical Pharmacology, 19, 231.
18. Desbene S., Dufat-Trinh Van H., Michel S., Koch M., Tillequin F., Fournier G., Farjaudon N., Monneret C. (1998) Hydrophilic doxorubicin prodrugs suited for tumour-selective activation. Anti-Cancer Drug Design, in press.
19. Florent J.-C., Dong X., Gaudel G., Mitaku S., Monneret C., Gesson J.-P., Jacquesy J.-C., Mondon M., Renoux B., Andrianomenjanahary S., Michel S., Koch M., Tillequin F., Gerken M., Czech J., Straub R., Bosslet K. (1998) Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy (ADEPT concept). Journal of Medicinal Chemistry, 41, 3572.
20. Fojo A., Ueda K., Slamon D., Poplack D., Gottesman M., Pastan I. (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proceedings of the National Academy of Sciences, USA, 84, 265.
21. Ford J. (1996) Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitizers. European Journal of Cancer, 32A, 991.
22. Gottesman M. (1993) How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Research, 53, 747.
23. Jacquesy J.-C., Gesson J.-P., Monneret C., Mondon M., Renoux B., Florent J.-C., Koch M., Tillequin F., Sedlacek H.S., Gerken M., Kolar C., Gaudel G., Bosslet K., Czech J., Hoffman D., Seemann G., Schorlemmer H.-U., Dickneite G. (1991) Prodrogues glycosylées. Patent FR Demand 91 05326.
24. Jacquesy J.-C., Gesson J.-P., Monneret C., Mondon M., Renoux B., Florent J.-C., Koch M., Tillequin F., Sedlacek H.S., Gerken M., Kolar C., Gaudel G., Bosslet K., Czech J., Hoffman D., Seemann G., Schorlemmer H.-U., Dickneite G. (1996) Glycosylated prodrugs, their method of preparation and their uses.US Patent 5,561,119.
25. Kavallaris M. (1997) The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance. Anti-Cancer Drugs, 8, 17.
26. Kaye S. (1993) P-Glycoprotein (P-gp) and drug resistance -time for reappraisal. British Journal of Cancer, 67, 641.
27. Melton R., Knox R., Connors T. (1996) Antibody-directed enzyme prodrug therapy (ADEPT). Drugs of the Future, 21, 167.
28. Niculescu-Duvaz I., Springer C. (1995) Antibody-directed enzyme prodrug therapy (ADEPT): a targeting strategy in cancer chemotherapy. Current Medicinal Chemistry, 2, 687.
29. Pearson K., Cunningham C. (1993) Multidrug resistance during cancer chemotherapy-biotechnological solutions to a clinical problem. Trends in Biotechnology, 11, 511.
30. Pennock G., Dalton W., Roeske W., Appleton C., Mosley K., Plezia P., Miller T., Salmon S. (1991) Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. Journal of the National Cancer Institute, 83, 105.
31. Raderer M., Scheithauer M. (1993) Clinical trials of agents that reverse multidrug resistance. Cancer, 72, 3553.
32. Reddy D. (1997) Development of multidrug resistance protein inhibitors. Drugs of the Future, 22, 653.
33. Robert J. (1994) Proposals for concomitant use of several modulators of multidrug resistance in clinics. Anticancer Research, 14, 2371.
34. Robert J. (1997) Multidrug resistance reversal agents. Drugs of the Future, 22, 149-158.
35. Sarkadi B., Müller M. (1997) Search for specific inhibitors of multidrug resistance in cancer. Cancer Biology, 8, 171.
36. Schmidt F., Florent J.-C., Monneret C., Straub R., Czech J., Gerken M., Bosslet K. (1997) Glucuronide prodrugs of hydroxy compounds for antibody directed enzyme prodrug therapy (ADEPT): a phenol nitrogen mustard carbamate. Bioorganic & Medicinal Chemistry Letters, 7, 1071.
37. Schmidt F., Florent J.-C., Monneret C. (1998) Synthèse et étude d'une prodrogue de dipyridamole: application de la stratégie ADEPT à la résistance multiple (MDR) en chimiothérapie anticancéreuse. Comptes Rendus de l'Académie des Sciences Paris, 1, série IIc, 421.
38. Senior A., Al-Shawi M., Urbatsch I. (1995) The catalytic cycle of P-glycoprotein. Federation of European Biochemical Societies Letters, 377, 285.
39. Sherwood R.F. (1996) Advanced drug delivery reviews: enzyme prodrug therapy. Advanced Drug Delivery Reviews, 22, 269.
40. Shoji Y., Fisher M., Periasamy A., Herman B., Juliano R. (1991) Verapamil and cyclosporin A modulate doxorubicin toxicity by distinct mechanisms. Cancer Letters, 57, 209.
41. Simon S., Schindler M. (1994) Cell biological mechanisms of multidrug resistance in tumors. Proceedings of the National Academy of Sciences, USA, 91, 3497.
42. Solary E., Caillot D., Chauffert B., Casasnovas R.-O., Dumas M., Maynadie M., Guy H. (1992) Feasibility of using quinine, a potential multridrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. Journal of Clinical Oncology, 10, 1730.
43. Springer C., Niculescu-Duvaz I. (1995) Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs. Anti-Cancer Drug Design, 10, 361.
44. Takimoto S., Inanaga J., Katsuki T., Yamaguchi M. (1976) Bulletin of the Chemical Society of Japan, 49, 2335.
45. Tsuruo T., Iiadi H., Tsukagoshi S., Sakurai Y. (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Research, 41, 1967.
46. Turner R.N., Curtin N.J. (1996) Dipyridamole increases VP16 growth inhibition accumulation and retention in parental and multidrug-resistant CHO cells. British Journal of Cancer, 73, 856.
47. van der Bliek, A.M., Borst P. (1989) Multidrug resistance. Advances in Cancer Research, 52, 165.
48. Yusa K., Tsuruo T. (1989) Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to p-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Research, 49, 5002.